| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AGH |
| Uniprot No | Q86SA8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-65aa |
| 氨基酸序列 | YQVEGMKSDVICADIRFTVHCICNELGRFPTARLTKPCPWPNRE |
| 预测分子量 | 20.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AGH重组蛋白的虚构参考文献示例(仅供格式参考，非真实文献)：
1. **《Expression and Characterization of Recombinant AGH Antimicrobial Peptide in E. coli》**
- 作者：Zhang Y, et al.
- 摘要：研究通过大肠杆菌系统高效表达AGH重组抗菌肽，并验证其对革兰氏阴性菌的抑菌活性，优化纯化工艺以提高产量。
2. **《Structural and Functional Analysis of AGH Recombinant Protein in Plant Defense》**
- 作者：Wang L, et al.
- 摘要：解析AGH重组蛋白的三维结构，探讨其在植物免疫应答中的作用机制，发现其通过激活茉莉酸信号通路增强抗病性。
3. **《AGH-Fusion Protein Enhances Drug Delivery Efficiency in Cancer Therapy》**
- 作者：Kim S, et al.
- 摘要：构建AGH与抗癌药物的融合蛋白，证明其能靶向肿瘤细胞并提高药物递送效率，体外实验显示显著抑制肿瘤增殖。
4. **《Biotechnological Production of AGH Protein Using Yeast Expression System》**
- 作者：García R, et al.
- 摘要：利用毕赤酵母系统规模化生产AGH重组蛋白，比较不同表达条件对蛋白活性的影响，为工业应用提供优化方案。
**备注**：以上内容为模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索关键词“AGH recombinant protein”或结合具体研究领域筛选。建议结合真实研究背景调整检索策略。
**Background of AGH Recombinant Protein**
AGH recombinant protein is a synthetic, multifunctional biomolecule engineered through recombinant DNA technology, designed to mimic or enhance natural protein functions. The acronym "AGH" typically refers to specific structural or functional domains within the protein, such as adhesion-promoting motifs (e.g., arginine-glycine-aspartic acid, RGD), glycosylation sites, or heparin-binding regions, though the exact composition may vary depending on its intended application. This class of recombinant proteins is often inspired by extracellular matrix (ECM) components, growth factors, or signaling molecules, aiming to bridge gaps in tissue engineering, regenerative medicine, and therapeutic delivery.
The development of AGH recombinant proteins arose from the need to overcome limitations of natural protein isolation, such as batch variability, immunogenicity, and pathogen risks associated with animal-derived materials. By leveraging genetic engineering, AGH proteins can be produced in microbial, mammalian, or insect cell systems, ensuring scalability, purity, and tailored functionality. For instance, AGH proteins may incorporate collagen-like domains for structural integrity, elastin-like polypeptides for elasticity, or cell-binding sequences to enhance biocompatibility.
Applications span diverse fields: in tissue engineering, AGH proteins serve as scaffolds to support cell adhesion and differentiation; in drug delivery, they act as carriers with targeting capabilities; and in wound healing, they promote angiogenesis and tissue repair. Their modular design allows customization for specific mechanical, chemical, or biological demands. Recent advances include fusion with smart polymers or nanomaterials to create stimuli-responsive systems.
Despite progress, challenges remain, including optimizing folding stability, minimizing off-target effects, and ensuring cost-effective production. Ongoing research focuses on improving bioactivity and exploring novel biomedical applications, positioning AGH recombinant proteins as versatile tools in next-generation therapeutics and biomaterials.
×
